Enquirer Consulting Group

Lax Sebenius Advisory Buyer Map

David Lax | Lax Sebenius | October 2026

As of 16 Oct 2026

You told us Lax Sebenius wants advisory clients, not training buyers, and that the people who sign off on each are very different.

This page maps the advisory side only: the organizations whose leaders face the high-stakes deals your site describes, by type and size, and who usually signs off on outside negotiation advice at each.

Where the advisory buyers sit

Groups drawn from the sectors and engagement types on the Lax Sebenius site. Advisory work on deals of this size usually sits with the larger firms, so the size columns matter more than the totals. Government and state-owned clients are not in these counts. A group with no clean public count says so.

GroupOrganizations in the USUnder 20 staff20 to 99100 to 499500 or more
Pharmaceutical and medicine makers (market access, licensing and business development deals)about 2,300about 1,400about 440about 290about 210
Oil and gas producers and electric power companies (exploration and development deals)about 6,700about 5,100about 960about 370about 220
Wired and wireless telecom carriersabout 8,400about 7,100about 930about 280about 130
Health and medical insurance carriersabout 1,100about 750about 73about 82about 170
Sponsors and developers of large infrastructure projectsno clean public count
Private equity firms negotiating acquisitions and exitsno clean public count

US firm counts by industry code, banded deliberately.

Who signs off on advisory work, by deal type

The deal types are the ones your advisory and services pages list. The person who signs is usually the one who owns the outcome of that one deal, not the one who owns training.

Deal on the tableWho usually signs offWho usually brings you in
Selling or buying a business, or a divisionCEO or CFO, with the boardHead of corporate development
Entering or exiting a joint venture or allianceCEO or business unit presidentHead of business development or alliances
Licensing and business development deals in pharmaChief business officerHead of business development and licensing
Market access for a drugChief commercial officerHead of market access
Settling a large lawsuit or shareholder class actionGeneral counsel, with the CEO and boardHead of litigation
Renegotiating supply chain or large procurement termsChief procurement officer or COOHead of strategic sourcing
Closing a large or complex sale, including with big retail chainsChief commercial or revenue officerHead of key accounts
Winning approval for a large infrastructure projectThe sponsor's CEO or head of developmentHead of government and regulatory affairs

Why these are not the training buyers

Training is often bought by HR or a functional head for a group. Advisory is bought by the executive who owns one deal, and judged on that deal's result.

That changes who to reach and when. The advisory buyer is easiest to reach while a deal is taking shape, before terms are set, and the first conversation is about that deal, not about negotiation in general.

Moments that open an advisory conversation

A company announces a strategic review of a business or division. A joint venture or alliance comes up for renewal or exit. A late-stage drug heads toward licensing talks or market access decisions. A large lawsuit moves toward settlement. A key supplier consolidates and pushes prices up. A major customer reopens terms.

Each of these has a named owner inside the company, usually one of the roles in the table above, and often a deadline.

Ten people to start with

The people who usually sign at the groups above, one a company. Work emails and phone numbers checked on Oct 16, 2026.

NameRoleCompanyWhereEmailPhone
Cheryl BallChief Strategy Officer, Head of Corporate DevelopmentLantheusBoston, MAcheryl.ball@lantheus.com+1 781 652 1615
Daniel SchnurmanHead of Corporate Development and StrategyViatrisNew Yorkdaniel.schnurman@viatris.com+1 347 343 0084
Amiel GrossGeneral CounselSK pharmtecoPhiladelphia, PA+1 267 472 2375
Jamal HaughtonExecutive Vice President, General Counsel & Corporate SecretaryCharter CommunicationsNew Yorkjamal.haughton@spectrum.com+1 201 615 2086
Adam ReedSVP, General Counsel and Corporate SecretaryTrucordiaGrand Rapids, MIadam@trucordia.com+1 616 541 1221
Nicholas SeminaraClaim General Counsel; Senior Vice President; Claim Legal, Subrogation andTravelersAvon, CTnicholas.seminara@travelers.com+1 860 990 4083
Nina HicksonGeneral CounselWSSC WaterAtlanta, GAnina.hickson@wsscwater.com+1 404 475 8650
Cari Almo GallmanExecutive Vice President, General Counsel and Chief Policy OfficerBristol Myers SquibbPrinceton, NJcari.gallman@bms.com+1 347 993 8471
Deneen DonnleySenior Vice President and General CounselCon EdisonNew Yorkdonnleyd@coned.com+1 212 460 1315
Deniz RazonChief Business OfficerServier PharmaceuticalsBoston+1 847 727 2005

Where to start

Lead with the live deal

Your services page says leaders who want support beyond their bankers and lawyers are often offered little more than rehearsal sessions. The cleanest opening is the head of corporate development or general counsel at a larger company with a deal taking shape, with one line on that deal and nothing about training.

Pharma licensing and market access

Your site names market access for pharma and business development and licensing negotiations among its engagement types. Chief business officers and heads of market access at the larger pharmaceutical and medicine makers face these deals often, which makes this a repeatable group.

Energy and infrastructure deals

Your site lists exploration and development deals and approvals for large infrastructure projects. Heads of business development at oil, gas and power companies, and the sponsors and developers behind large infrastructure projects, own those negotiations and the timelines behind them.

Built from public federal statistics and the Lax Sebenius website, counts banded deliberately.

If a walk-through is useful, pick a time at cal.com/ecg.

Prepared by Ben Beattie, ben@enquirerconsulting.com.